Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia
BMC Public Health volume 21, Article number: 503 (2021)
Governments worldwide recommended unprecedented measures to contain the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As pressure mounted to scale back measures, understanding public priorities was critical. We assessed initial public adherence with and support for stay-at-home orders in nations and cities with different SARS-CoV-2 infection and COVID-19 death rates.
Cross-sectional surveys were administered to representative samples of adults aged ≥18 years from regions with different SARS-CoV-2 prevalences from April 2–8, 2020. Regions included two nations [the United States (US—high prevalence) and Australia (AU—low prevalence)] and two US cities [New York City (NY—high prevalence) and Los Angeles (LA—low prevalence)]. Regional SARS-CoV-2 and COVID-19 prevalence (cumulative SARS-CoV-2 infections, COVID-19 deaths) as of April 8, 2020: US (363,321, 10,845), AU (5956, 45), NY (81,803, 4571), LA (7530, 198). Of 8718 eligible potential respondents, 5573 (response rate, 63.9%) completed surveys. Median age was 47 years (range, 18–89); 3039 (54.5%) were female.
Of 5573 total respondents, 4560 (81.8%) reported adherence with recommended quarantine or stay-at-home policies (range of samples, 75.5–88.2%). Additionally, 29.1% of respondents screened positive for anxiety or depression symptoms (range of samples, 28.6–32.0%), with higher prevalences among those of younger age, female gender, and those in quarantine or staying at home most of the time versus those who did not report these behaviours. Despite elevated prevalences of adverse mental health symptoms and significant life disruptions, 5022 respondents (90.1%) supported government-imposed stay-at-home orders (range of samples, 88.9–93.1%). Of these, 90.8% believed orders should last at least three more weeks or until public health or government officials recommended, with support spanning the political spectrum.
Public adherence with COVID-19 mitigation policies was highly prevalent, in both highly-affected (US, NY) and minimally-affected regions (AU, LA). Despite disruption of respondents’ lives, the vast majority supported continuation of extended stay-at-home orders. Despite common support, these two countries diverged in stringent mitigation implementation, which may have contributed to subsequent outcomes. These results reveal the importance of surveillance of public support for and adherence with such policies during the COVID-19 pandemic and for future infectious disease outbreaks.
As of 7 March 2021, there have been 116 million confirmed cases of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, which have contributed to nearly 2.6 million deaths from coronavirus disease 2019 (COVID-19) . In March 2020, during the initial phase of the COVID-19 pandemic and absent widespread testing, safe and efficacious treatments or protective vaccines, isolation and quarantine were recommended worldwide for the first time in a century. SARS-CoV-2 prevalence and associated public health policies have varied across jurisdictions and changed over time, largely without systematic assessment of public responses to the crisis or the mitigation strategies. To provide policymakers with public priorities and perspectives, we conducted a transnational cross-sectional study to assess public adherence with and support for government-imposed stay-at-home orders among individuals from regions with varying SARS-CoV-2 prevalence, including two nations [the United States (US—high SARS-CoV-2 prevalence) and Australia (AU—low SARS-CoV-2 prevalence)] and two cities [New York City (NY—high SARS-CoV-2 prevalence) and Los Angeles (LA—low SARS-CoV-2 prevalence)]. The aims of this analysis were to assess the following in the initial stages of the pandemic: public adherence with and support for stringent COVID-19 mitigation policies, including stay-at-home orders; public concerns and experiences related to the pandemic and its mitigation; and mental health, including symptoms of anxiety, depression, and insomnia. We also sought to identify characteristics associated with non-support for and non-adherence with mitigation strategies and with adverse mental health symptoms during the COVID-19 pandemic.
Study design and recruitment
To evaluate public adherence with and support for recommended COVID-19 mitigation strategies, we collected cross-sectional surveys of nationally representative samples of respondents using demographic quota sampling . Surveys were administered to online respondent panels by Qualtrics, LLC (Provo, Utah, and Seattle, Washington, US), a commercial survey company with a network of participants consisting of hundreds of suppliers. Recruitment methodologies include digital advertisements and promotions, word of mouth, membership referrals, social networks, TV & radio advertisements, and offline approaches.
Between April 2–8, 2020 (a one-week interval), respondents were recruited from regions with markedly different infection and death rates from COVID-19 (Table 1), including nationwide samples in the US (high SARS-CoV-2 prevalence) and AU (low SARS-CoV-2 prevalence), and citywide samples in the NY (high SARS-CoV-2 prevalence) and LA (low SARS-CoV-2 prevalence) metropolitan areas. Data reported from the US sample exclude respondents from the separate NY and LA samples, unless otherwise noted.
Study approval and informed consent
The study protocol was approved by the Monash University Human Research Ethics Committee (#24036) and conducted in accordance with ethical guidelines. This activity was also reviewed by the United States Centers for Disease Control and Prevention (CDC), which affirmed that the activity was conducted consistent with applicable federal law and CDC policies for the protection of human participants from research risks: 45 Code of Federal Regulations (CFR) part 46, 21 CFR part 56; 42 United States Code (USC) Section 241(d); 5 USC Section 552a; 44 USC Section 3501 et seq. Respondents were informed of the study purposes and provided informed electronic consent prior to commencement. Investigators received anonymised responses.
Target numbers of respondent-completed surveys follow: US (3000), NY (500), LA (500), AU (1500). These sample sizes were selected to obtain samples with margins of error at 95% confidence levels of ±1.8, ±4.4, ±4.4, and ± 2.5%, respectively. To be eligible to participate, respondents were required to have provided informed electronic consent and to have reported being aged ≥18 years with current residence in the specified regions. Demographic sampling quotas were implemented for age, gender, and either race and ethnicity (US, NY, LA) or ancestry (AU), based on 2010 US and 2016 Australian census national population estimates. Potential respondents likely to qualify based on demographic characteristics listed in their Qualtrics panellist profile were targeted during recruitment; demographic questions (gender, age, race, ethnicity, and ancestry) were included in the survey to confirm eligibility. Potential respondents received invitations and could opt to participate by activating a survey link directing them to the participant information and consent page preceding the survey. Ineligible respondents who did not meet inclusion criteria (eg, aged < 18 years, not a resident of a targeted region) or exceeded pre-set quotas (ie, maximum demographic characteristic quota already met) were disempanelled.
The surveys contained 86 [US, NY, LA] or 85 [adapted for AU] items, with each item requiring a response, and was designed to take approximately 15 min to complete. Respondents were required to self-report demographic characteristics and respond to questions about COVID-19 and mitigation strategies, including adherence, priorities, sources of concern, and comparisons of current lifestyle versus lifestyle between October and December 2019 (ie, before COVID-19 and COVID-19 mitigation strategies). Additional health-related questions were asked independent of COVID-19. When possible, brief validated instruments were used, including the Short-Form Sleep Condition Indicator (SCI-02) for insomnia symptom assessment, Patient Health Questionnaire-4 (PHQ-4) for anxiety and depression symptom assessment, the Perceived Stress Scale-4 (PSS-4) for perceived stress assessment, and the Mini Z for burnout symptom assessment [7,8,9,10]. When required, validated instruments were adapted, including the Horne and Östberg Morningness-Eveningness Questionnaire (MEQ) for chronotype assessment, the μshort Munich ChronoType Questionnaire (μMCTQ) for chronotype and sleep behaviour assessment, Obstructive Sleep Apnoea 50 (OSA50) for obstructive sleep apnoea risk assessment, single-item physical activity measure, and Hurt-Insult-Threaten-Scream (HITS) screening tool for domestic violence [11,12,13,14,15,16].
To verify response quality, Qualtrics conducted standardised quality screening and data cleaning procedures. Techniques included algorithmic analysis for attention patterns, click-through behaviour, duplicate responses, keystroke analysis, machine responses, and inattentiveness. Country-specific geolocation verification via IP address mapping was used to ensure respondents were from the country specified in their response. Respondents who failed an attention or speed check, along with any responses identified by the data scrubbing algorithms, were excluded from the final sample.
Descriptive summary data are reported overall and by each sample. Multivariable Poisson regression models with robust standard errors were used to estimate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for mitigation behaviours adjusted for the following explanatory variables: gender, age, political ideology, and nation (US or Australia) or city (New York or Los Angeles). For the multivariable analysis, respondents who reported a gender other than Male or Female (ie, “Other,” n = 4 [2 in the US sample, 2 in the Australian sample]) were excluded due to small cell sizes. The nation or city variable was used to account for differences in these sample populations, including SARS-CoV-2 and COVID-19 prevalence, mitigation policies, and other cultural or regional differences. In the cities model, combined race/ethnicity was also included as an explanatory variable. Employment status and marital status were excluded from the models to avoid collinearity with age. Separate models were run with dependent variables of having not self-reported quarantine or spending most of the time at home and having not supported stay-at-home orders as dependent variables. Additional models were run to estimate aPRs and 95% CIs for anxiety or depressive disorder symptoms and for insomnia symptoms with the same explanatory variables, plus a variable indicating whether respondents self-reported having been in quarantine or spending most of time at home. Python (version 3.7.8; Python Software Foundation) and the Python statsmodels package were used to conduct all analyses. Statistical significance was determined as p < 0.05.
Between April 2 and April 8, 2020, of 8717 eligible invited adults, 5573 (63.9%) completed surveys (Fig. 1). The regional number of respondents, response rates, and 95% confidence level margins of error follow: US: n = 3010, response rate = 64.1%, margin of error = ±1.8%; NY: 507, response rate = 53.2%, margin of error = ±4.4%; LA: 525, response rate = 58.6%, margin of error = ±4.3%; AU: 1531, response rate = 70.6%, margin of error = ±2.5%. Overall, 3039 (54.5%) respondents were female; the median age of participants was 47 years (range, 18–89). Respondent demographic characteristics of categories with and without pre-specified quotas are reported in Tables 2 and 3, respectively. The state- and territory-level geographic distributions of respondents’ residency for each nationwide sample are reported in Additional file 1 online. Respondents’ personal experiences with COVID-19 and knowledge of others’ experiences with COVID-19 (Table 4) were consistent with the samples having recruited respondents with residence in regions with markedly different regional SARS-CoV-2 infection and COVID-19 death rates. NY had the highest percentage of respondents who reported knowing someone who had tested positive for SARS-CoV-2 (27.0% vs. 5.6–11.0% for the rest of the samples), or who had been hospitalised for (14.6% vs. 2.4–6.5% for the rest of the samples) or died from (9.5% vs. 0.7–2.9% for the rest of the samples) COVID-19.
Respondents’ COVID-19-mitigation adherence, public priorities, life impact, and mental health symptoms are illustrated in Figs. 2, 3, 4. Altogether, 4560 respondents (81.8%) reported having been in quarantine or spending the majority of time at home (range of samples, 75.5–88.2%) (Fig. 2, Table 5). Moreover, 5022 (90.1%) believed a government-imposed stay-at-home order was warranted (range of samples, 88.9–93.1%). Of these, 90.8% believed the order should have lasted at least 3 weeks (9.1%), a month or longer (43.8%), or until public health (31.1%) or government officials (6.8%) determined it was safe to lift the restrictions. Of 5304 respondents (95.2%) who made predictions, the average predicted date by which COVID-19 would no longer affect their daily lives was between mid-June 2020 and mid-August 2020, though there was high variability in predictions (Table 5). Strong support for government-imposed stay-at-home orders spanned the political spectrum.
In the nations model for non-adherence with mitigation policies, respondents of female versus male gender and aged 18–24 years versus ≥65 years significantly less commonly reported neither being in quarantine nor spending the majority of time at home (Table 6). Compared to those with centrist liberal ideology, liberal respondents less commonly reported non-adherence, while very conservative respondents more commonly reported this behaviour. Respondents from the US also less commonly reported non-adherence than those from Australia. In the cities model, the gender difference was also observed. No other characteristics were associated with significant differences.
In the nations model, the gender effect was similar for non-support for stay-at-home orders, with female significantly less commonly having reported not supporting such measures (aPR = 0.67, 95% CI = 0.57–0.80, p < 0.001) (Table 6). However, the age effect was reversed, with all younger age groups more commonly reporting non-support for stay-at-home orders than those aged ≥65 years (eg, 18–24 years, 1.83, 1.30–2.56, p < 0.001). In the city samples, many of the aPRs are of similar magnitude and direction to the nation samples, though statistical significance was not reached. However, in contrast to the nationwide samples, in the cities model, both slightly and very conservative respondents had more than 2-fold increased prevalence of non-support than those with centred political ideology. Statistically significant differences in non-support for stay-at-home orders were not observed regionally.
Broad support for stringent mitigation policies was reported despite elevated prevalences of adverse mental health symptoms compared with pre-pandemic estimates using similar screening instruments. Overall, 1303 respondents (23.4%, range of samples, 22.1–25.4%) screened positive for symptoms of an anxiety disorder and 1172 (21.0%, range of samples, 20.0–22.7%) screened positive for symptoms of a depressive disorder, with 1622 participants (29.1%, range of samples, 28.6–32.0%) having screened positive for symptoms of at least one of these adverse mental health conditions (Table 7). Moreover, 1029 respondents (18.5%, range of samples, 15.2–20.0%) screened positive for insomnia symptoms.
Multivariable analysis of adverse mental health symptoms in the nation and cities models revealed that symptoms of anxiety or depressive disorders were more common among adults of female versus male gender (eg, cities model, aPR = 1.49, 95% CI = 1.23–1.81) and younger versus older age (eg, 18–24 versus ≥65 years, cities model, 3.28, 2.20–4.90), with all p ≤ 0.001 (Table 8). There were also differences by adherence with COVID-19 mitigation measures. In the nations model, symptoms of anxiety or depressive disorders were more common among those who reported being in quarantine or voluntarily spending the majority of time at home (1.77, 1.52–2.05 and 1.32, 1.14–1.53, respectively, both p < 0.001) versus those doing neither of these. The magnitudes of both aPRs were similar in the cities model, though adjusted prevalence of those spending the majority of time at home was not statistically significant. Very liberal respondents more commonly experienced anxiety or depressive disorder symptoms in both models. Insomnia symptoms were also more common among female versus male respondents (eg, cities model, 1.81, 1.35–2.42, p < 0.001), while the only difference by age group was observed among those aged 45–65 versus ≥65 years in the nations model (1.25, 1.04–1.49, p = 0.015). In the nations model but not the cities model, insomnia symptoms were more common among those who reported being in quarantine or voluntarily spending the majority of time at home (1.36, 1.13–1.65, p = 0.001 and 1.22, 1.02–1.46, p = 0.027, respectively) versus those doing neither of these. Statistically significant differences were not observed for adverse mental health symptoms regionally.
In addition to symptoms of anxiety, depression, and insomnia, many respondents reported COVID-19-specific concerns, as 4431 respondents (79.5%, range of samples, 77.5–82.1%) reported moderate to extreme concern about their own (61.9%) or others’ (75.5%) infection with SARS-CoV-2, and 3974 (71.3%, range of samples, 69.8–76.0%) reported similar concerns about their own (43.4%) or others’ (68.7%) death due to COVID-19 (Fig. 2). Access to testing (59.3%), medical care for COVID-19 (64.5%), medical care for pre-existing conditions due to hospital overload (59.2%), social or physical isolation (58.1%), and sense of purpose (49.8%) were also sources of moderate to extreme concern. Overall, 1217 respondents (21.8%) identified as high risk for severe COVID-19 infection. Across regions, nearly half (42.0–45.3%) reported spending considerable time (average, 23.2 h per week) consuming information (media, government reports, health officials, family) about COVID-19. Moreover, widespread concerns included the possibility of an economic recession and open-endedness of COVID-19 mitigation measures (79.2 and 72.2%, respectively) (Fig. 2).
Consistent across regions, respondents reported that COVID-19 and mitigation strategies have caused moderate to extreme disruption of social life (75.3%), family life (41.0%), work/studies (43.5%), productivity (41.6%), physical activity (45.1%), sexual activity (23.6%), and sleep patterns (39.3%) (Fig. 3). Overall, 1999 respondents (35.9%) reported exercising less frequently, and 409 (7.4%) reported concerning weight gain (Fig. 4). Daily outdoor light exposure was reduced by 1 h or more in 2279 respondents (40.9%). The estimated percentage of virtual interactions (versus face-to-face) increased from 14.6 to 66.1%, and 1786 respondents (32.0%) reported more than 1 h increase in daily screen time.
Resounding adherence with and support for strict COVID-19 mitigation measures was demonstrated in representative samples from the United States and Australia, despite the broad disruption these mitigation measures had on their social lives and daily routines, and their concerns about the economic consequences of such measures. Although 91.4% of respondents reported they believed they would never be infected with SARS-CoV-2 (range of samples, 89.2–92.6%), controlling COVID-19 was a top public priority at the outset of the pandemic. Contrary to negative public attitudes about and low adherence with recommended mitigation during the last pandemic [17, 18] declared by the World Health Organization for novel influenza A (H1N1) in 2009 , the initial public response to the COVID-19 pandemic represented a hitherto unprecedented level of adherence with public health emergency measures that has had and will continue to have a profound impact on economics and public life.
These results demonstrate an enhanced public adherence with stay-at-home orders in the US compared to reported adherence during the weeks before such orders were initially widely implemented . Recently published data from a convenience sample suggest that one month later (May 2020), nearly half of adults in the UK were intentionally non-adherent with government-imposed mitigation measures . Differences in the survey sampling methodology, the questions used to assess adherence with mitigation policies, recruitment timeframe, and study populations make it difficult to make direct comparisons of these results, however, which are not consistent with our findings in May 2020 among US adults, who reported sustained adherence to and support for stay-at-home orders and nonessential business closures . Our findings represent one of the earliest assessments of mental health and life impact of the COVID-19 pandemic and its mitigation, having been administered in early April 2020, near the onset of initial stay-at-home orders in the US and Australia. They reveal that the adverse life impact and mental health symptoms observed throughout the pandemic—including significant disruption of daily life and two- to three-fold increased prevalences of anxiety and depressive disorder symptoms compared with pre-pandemic estimates [23,24,25,26,27,28,29,30,31]—were evident within a month after the pandemic was declared by the WHO, in regions and countries with both high and low prevalences of COVID-19. These broad impacts of the COVID-19 pandemic and its mitigation are similar to those observed during previous infectious disease outbreaks [32,33,34]. These findings may also provide insight into behavioural countermeasures related to sleep, exercise, and diet that may reduce adverse health consequences of COVID-19 mitigation measures.
Strengths of this study include rapid and largescale assessment of public adherence, priorities, and life impacts related to COVID-19 and its mitigation in representative samples from developed nations and cities with high and low SARS-CoV-2 prevalences near the onset of the pandemic and widespread stay-at-home orders, enabling comparisons across jurisdictions at a simultaneous timepoint using consistent questions. Limitations include self-report measures of behaviours, which are subject to recall, response, and social desirability biases. Survey samples also have potential non-response and self-selection biases among respondents, and while quota sampling was used to improve sample representativeness in each region, Internet-based samples may not fully represent the 2020 US and Australian populations. However, the high response rate (63.9%) and consistency of responses across cities and countries despite vastly different rates of SARS-CoV-2 infection, governments, and mitigation strategies support the robustness of our findings.
As controversies over the legality  and balance between duration and nature of mitigation strategies and related consequences mounted following their implementation in the second quarter of 2020, with the prospect of repeated and protracted stay-at-home orders being recommended over the next 2 years , rigorous assessment of public priorities, adherence, and life impact will be paramount. Over the past year, Australia capitalized on the broad support for stringent mitigation measures documented herein, implementing widescale testing, contact tracing, and, in some cases, strict mitigation measures (eg, mandatory mask usage in public, physical distancing, and quarantining as necessary to contain regional outbreaks). In contrast, the United States did not capitalize on this broad initial support for stringent mitigation measures, which were effective in reducing community mobility  and slowing community transmission of SARS-CoV-2 . Jurisdictions across the US opted instead to lift restrictions, which was associated with increased mobility , before testing for SARS-CoV-2 infection was readily available and widespread community transmission of COVID-19 was contained. These are among policies that a recent Lancet Commission deemed to have substantially contributed to excess preventable COVID-19 deaths in the US compared with other high-income countries . Notably, as of December 27, 2020, the cumulative COVID-19 death rate in Australia was 3.6 deaths per 100,000 population, with 0 new deaths in the prior week, and the COVID-19 death rate in the United States was 99.1 deaths per 100,000 population, with 16,864 new deaths in the prior week (5.1 deaths per 100,000 population) . The weekly death rate in the US in the last full week of December was more than 40% greater than the cumulative per capita death rate during the entire pandemic in Australia.
In early April 2020, within 1 month of the declaration of the COVID-19 pandemic, US and Australian adults reported widespread adherence with stringent mitigation policies, and strongly supported continued government-imposed stay-at-home orders for as long as necessary to contain the COVID-19 pandemic, despite the considerable sacrifices that these measures required, and the potentially significant economic consequences. Markedly elevated prevalences of adverse mental health symptoms compared to pre-pandemic estimates were found in both nations and cities, and an extensive degree of life disruption attributed to COVID-19 was documented. These data highlight that respondents of younger age, female gender, and those in quarantine or spending most of the time at home more commonly experienced anxiety and depression symptoms than persons of other demographic groups, regardless of whether they were in regions with high or low SARS-CoV-2 prevalence. Timely dissemination of routine surveillance of public attitudes, behaviours, and beliefs regarding mitigation measures that require public support and adherence is important to inform strategies to improve adherence. They further underscore the importance of assessment of the potential life and mental health impacts of the pandemic and its mitigation, and may be used to inform policymakers during both the current and future infectious disease outbreaks.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.
Coronavirus disease 2019
2-item Generalized Anxiety Disorder
Novel influenza A
Los Angeles metropolitan area
New York City metropolitan area
Obstructive Sleep Apnoea 50
2-item Patient Health Questionnaire
4-item Patient Health Questionnaire
4-item Perceived Stress Scale
Short-Form Sleep Condition Indicator
μshort Munich ChronoType Questionnaire
United States of America
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;S1473–3099(20):30120–1 https://doi.org/10.1016/S1473-3099(20)30120-1.
Miller CA, Guidry JPD, Dahman B, Thomson MD. A tale of two diverse qualtrics samples: information for online survey researchers. Cancer Epidemiol Biomark Prev. 2020;29(4):731–5 https://doi.org/10.1158/1055-9965.EPI-19-0846.
Coronavirus disease 2019 (COVID-19) Situation Report – 73. World Health Organization. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200402-sitrep-73-covid-19.pdf?sfvrsn=5ae25bc7_6. Accessed 10 Apr 2020.
Coronavirus disease 2019 (COVID-19) Situation Report – 76. World Health Organization. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200405-sitrep-76-covid-19.pdf?sfvrsn=6ecf0977_4. Accessed 10 Apr 2020.
Coronavirus disease 2019 (COVID-19) Situation Report – 79. World Health Organization. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200408-sitrep-79-covid-19.pdf?sfvrsn=4796b143_6. Accessed 10 Apr 2020.
Coronavirus (Covid-19) Data in the United States. The New York Times. https://github.com/nytimes/covid-19-data. Accessed 10 Apr 2020.
Espie CA, et al. The sleep condition Indicator: a clinical screening tool to evaluate insomnia disorder. BMJ Open. 2014;4(3):e004183 https://doi.org/10.1136/bmjopen-2013-004183.
Löwe B, et al. A 4-item measure of depression and anxiety: validation and standardization of the patient health Questionnaire-4 (PHQ-4) in the general population. J Affect Discord. 2010;122(1–2):86–95 https://doi.org/10.1016/j.jad.2009.06.019.
Lee E-H. Review of the psychometric evidence of the perceived stress scale. Asian Nurs Res. 2012;6(4):121–7 https://doi.org/10.1016/j.anr.2012.08.004.
Dolan ED, et al. Using a single item to measure burnout in primary care staff: a psychometric evaluation. J Gen Intern Med. 2015;30(5):582–7 https://doi.org/10.1007/s11606-014-3112-6.
Horne JA, Östberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97–110.
Ghotbi N, et al. The μMCTQ: an ultra-short version of the Munich ChronoType questionnaire. J Biol Rhythm. 2019;35(1):98–110 https://doi.org/10.1177/0748730419886986.
Chai-Coetzer CL, et al. A simplified model of screening questionnaire and home monitoring for obstructive sleep apnoea in primary care. Thorax. 2011;66(3):213–9 https://doi.org/10.1136/thx.2010.152801.
Milton K, Bull FC, Bauman A. Reliability and validity testing of a single-item physical activity measure. Br J Sports Med. 2011;45(3):203–8 https://doi.org/10.1136/bjsm.2009.068395.
Sherin KM, Sinacore JM, Li XQ, Zitter RE, Shakil AHITS. a short domestic violence screening tool for use in a family practice setting. Fam Med. 1998;30(7):508–12.
Shakil A, Donald S, Sinacore JM, Krepcho M. Validation of the HITS domestic violence screening tool with males. Fam Med. 2005;37(3):193–8.
Jhummon-Mahadnac ND, Knott J. Marshall C. A cross-sectional study of pandemic influenza health literacy and the effect of a public health campaign. BMC Res Notes. 2012;5:377 https://doi.org/10.1186/1756-0500-5-377.
Kavanagh AM, et al. Sources, perceived usefulness and understanding of information disseminated to families who entered home quarantine during the H1N1 pandemic in Victoria, Australia: a cross-sectional study. BMC Infect Dis. 2011;11(2) https://doi.org/10.1186/1471-2334-11-2.
World now at the start of 2009 influenza pandemic. World Health Organization. 2009. https://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/. Accessed 13 Apr 2020.
Nelson LM, et al. US public concerns about the COVID-19 pandemic from results of a survey given via social media. JAMA Intern Med. 2020:e201369 https://doi.org/10.1001/jamainternmed.2020.1369.
Hills S, Eraso Y. Factors associated with non-adherence to social distancing rules during the COVID-19 pandemic: a logistic regression analysis. BMC Public Health. 2021;21(1):352. https://doi.org/10.1186/s12889-021-10379-7.
Czeisler MÉ, Tynan MA, Howard ME, et al. Public Attitudes, Behaviors, and Beliefs Related to COVID-19, Stay-at-Home Orders, Nonessential Business Closures, and Public Health Guidance — United States, New York City, and Los Angeles, May 5–12, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:751–758. https://doi.org/10.15585/mmwr.mm6924e1.
Czeisler MÉ, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic — United States, June 24–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1049–57 https://doi.org/10.15585/mmwr.mm6932a1.
CDC, National Center for Health Statistics. Indicators of anxiety or depression based on reported frequency of symptoms during the last 7 days. Household Pulse Survey. Atlanta: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020. https://www.cdc.gov/nchs/covid19/pulse/mental-health.htm. Accessed 31 Dec 2020
CDC, National Center for Health Statistics. Early release of selected mental health estimates based on data from the January–June 2019 National Health Interview Survey. Atlanta: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020. https://www.cdc.gov/nchs/data/nhis/earlyrelease/ERmentalhealth-508.pdf. Accessed 31 Dec 2020
Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686 https://doi.org/10.1001/jamanetworkopen.2020.19686.
Czeisler MÉ, Lane RI, Wiley JF, et al. Follow-up survey of US adult reports of mental health, substance use, and suicidal ideation during the COVID-19 pandemic, September 2020. JAMA Netw Open. 2021;4(2):e2037665. https://doi.org/10.1001/jamanetworkopen.2020.37665.
Czeisler MÉ, Howard ME, Rajaratnam SMW. Mental health during the COVID-19 pandemic: challenges, populations at risk, implications, and opportunities. Am J Health Promot. 2021;35(2):301–11 https://doi.org/10.1177/0890117120983982b.
Wang C, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17(5):e1729 https://doi.org/10.3390/ijerph17051729.
Li S, Wang Y, Xue J, Zhao N, Zhu T. The impact of COVID-19 epidemic declaration on psychological consequences: a study on active Weibo users. Int J Environ Res Public Health. 2020; https://doi.org/10.3390/ijerph17062032.
Shevlin M, McBride O, Murphy J, et al. Anxiety, depression, traumatic stress and COVID-19-related anxiety in the UK general population during the COVID-19 pandemic. BJPsych Open. 2020;6(6):e125. https://doi.org/10.1192/bjo.2020.109.
Hawryluck L, et al. SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis. 2004;10:1206–12 https://doi.org/10.3201/eid1007.030703.
Van Bortel T, et al. Psychosocial effects of an Ebola outbreak at individual, community and international levels. Bull World Health Organ. 2016;94:210–4 https://doi.org/10.2471/BLT.15.158543.
Brooks SK, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020; https://doi.org/10.1016/S0140-6736(20)30460-8.
Parmet WE, Sinha MS. Covid-19 - the law and limits of quarantine. N Engl J Med. 2020; https://doi.org/10.1056/nejmp2004211.
Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020; https://doi.org/10.1126/science.abb5793.
Lasry A, Kidder D, Hast M, et al. Timing of Community Mitigation and Changes in Reported COVID-19 and Community Mobility - Four U.S. Metropolitan Areas, February 26-April 1, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):451–7. https://doi.org/10.15585/mmwr.mm6915e2.
Ebrahim S, Ashworth H, Noah C, Kadambi A, Toumi A, Chhatwal J. Reduction of COVID-19 Incidence and Nonpharmacologic Interventions: Analysis Using a US County-Level Policy Data Set. J Med Internet Res. 2020;22(12):e24614. https://doi.org/10.2196/24614.
Moreland A, Herlihy C, Tynan MA, et al. Timing of State and Territorial COVID-19 Stay-at-Home Orders and Changes in Population Movement - United States, March 1-May 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(35):1198–203. https://doi.org/10.15585/mmwr.mm6935a2.
Woolhandler S, Himmelstein DU, Ahmed S, et al. Public policy and health in the Trump era. Lancet. 2021:S0140-6736(20)32545-9 https://doi.org/10.1016/S0140-6736(20)32545-9.
Coronavirus disease 2019 (COVID-19) weekly epidemiological update - 29 December 2020. World Health Organization. 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update%2D%2D-29-december-2020.
Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2019 (NST-EST2019–01). U.S. Census Bureau, Population Division. 2019. https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-total.html. Accessed 25 Apr 2020.
3101.0 - Australian demographic statistics, Sep 2019. Australian Bureau of Statistics. 2020. https://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3101.0Main%20Features3Sep%202019?opendocument&tabname=Summary&prodno=3101.0&issue=Sep%202019&num=&view=.
We thank the survey respondents, as well as Mallory Colys, Sneha Baste, Daniel Chong, and Rebecca Toll of Qualtrics, LLC, for their support of survey administration and data collection.
This study was supported in part by the Institute for Breathing and Sleep, Austin Health; the Turner Institute for Brain and Mental Health, Monash University; and by a gift to the Harvard Medical School from Philips Respironics. MÉC was supported by a 2020 Fulbright Scholarship funded by The Kinghorn Foundation through the Australian-American Fulbright Commission. ERF-C was supported by a Commonwealth Scientific and Industrial Research Organisation STEM+ Business Fellowship funded through the Science and Industry Endowment Fund. LKB and CAC were supported in part by the National Institute of Occupational Safety and Health R01-OH-010300. CAC was supported in part by the National Institue on Aging P01-AG09975 and serves as the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. The funders were not involved in the design and conduct of the study, the collection, preparation, or interpretation of the data, or the preparation or approval of the manuscript.
Ethics approval and consent to participate
The study protocol was approved by the Monash University Human Research Ethics Committee (#24036) and conducted in accordance with ethical guidelines. This activity was also reviewed by the United States Centers for Disease Control and Prevention (CDC), which affirmed that the activity was conducted consistent with applicable federal law and CDC policies for the protection of human participants from research risks: 45 Code of Federal Regulations (CFR) part 46, 21 CFR part 56; 42 United States Code (USC) Section 241(d); 5 USC Section 552a; 44 USC Section 3501 et seq. Respondents were informed of the study purposes and provided informed consent electronically prior to commencement. Investigators received anonymised responses.
Consent for publication
CAC reports grants from Cephalon Inc., Jazz Pharmaceuticals Plc., Inc., Philips Respironics, Inc., Regeneron Pharmaceuticals, and Sanofi S.A.; and personal fees from Institute of Digital Media and Child Development, Klarman Family Foundation, Teva Pharma Australia, and Vanda Pharmaceuticals. In addition, CAC holds an equity interest in Vanda Pharmaceuticals, Inc. CAC receives royalties from Philips Respironics, Inc. for the Actiwatch-2 and Actiwatch-Spectrum devices. Interests for CAC were reviewed and managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies. MÉC, MEH, RR, LKB, ERF-C, and SMWR declare no potential conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Respondent 2019 Place of Residency in Nationwide Samples. Description of data: Respondents reported their primary place of residence between October and December 2019. For the nationwide US sample, the distribution of respondents among the fifty states and Washington District of Columbia are reported in comparison to population estimates from the US Census Bureau as of July 2019 . For the nationwide AU sample, the distribution of respondents among the six states and two internal territories are reported in comparison to population estimates from the AU Bureau of Statistics as of September 2019 . In total, 44/4541 respondents (0.97%) lived outside of the US or AU between October and December 2019 and were currently residing in these regions. These data support the nationwide samples as geographically representative by state or territory.
About this article
Cite this article
Czeisler, M.É., Howard, M.E., Robbins, R. et al. Early public adherence with and support for stay-at-home COVID-19 mitigation strategies despite adverse life impact: a transnational cross-sectional survey study in the United States and Australia. BMC Public Health 21, 503 (2021). https://doi.org/10.1186/s12889-021-10410-x